Short Bowel Syndrome: Clinical Trials

35 trials for Short Bowel Syndrome, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

25 completed, 4 active not recruiting, 2 recruiting, 2 terminated. 35 Phase 3, 3 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 335Completed 25, Active not recruiting 4, Recruiting 2, Terminated 2, Withdrawn 2
Phase 23Completed 2, Terminated 1

Follow Short Bowel Syndrome: new trials by email Literature Review of Short Bowel Syndrome trials Research Report on Short Bowel Syndrome

Trials (filtered) newest first · largest first

All 35 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study to Investigate the Efficacy and Safety of Apraglutide Compared With Placebo in Adult Participants With Short Bowel Syndrome Associated With Intestinal Failure (SBS-IF)
Apraglutide, Placebo - Short Bowel Syndrome (SBS), SBS Associated With Intestinal Failure (SBS-IF)
Phase 3RecruitingVectivBio AG1242026-08-012026-08-04
Efficacy And Safety Evaluation of Glepaglutide in Treatment of SBS
Glepaglutide, Placebo - Short Bowel Syndrome
Phase 3RecruitingZealand Pharma902026-02-112026-09-29
Efficacy and Safety Evaluation of Glepaglutide in Treatment of Short Bowel Syndrome
Glepaglutide 10 mg - Short Bowel Syndrome (SBS)
Phase 3Active not recruitingZealand Pharma282025-12-112026-07-30
A Study of Teduglutide in Chinese Adults With Short Bowel Syndrome
Teduglutide - Short Bowel Syndrome
Phase 3Active not recruitingTakeda132025-06-262026-09-08
Efficacy and Safety of PJ009 in Patients With Short Bowel Syndrome Requiring Parenteral Nutrition
PJ009, PJ009 Placebo - Short Bowel Syndrome
Phase 3Active not recruitingChongqing Peg-Bio Biopharm Co., Ltd.722024-09-032026-10-22
A Study of Teduglutide in Japanese Children With Short Bowel Syndrome Aged 4 Months or Older
Teduglutide - Short Bowel Syndrome
Phase 3CompletedTakeda32022-01-042024-05-16
The Long-term Effect on Intestinal Absorption and Safety of Treatment With Glepaglutide in Patients With Short Bowel Syndrome
Glepaglutide - Short Bowel Syndrome
Phase 3CompletedZealand Pharma122021-08-102024-11-22
Open-label Extension Trial to Evaluate the Long-term Safety of Apraglutide in Short Bowel Syndrome.
Apraglutide - Short Bowel Syndrome
Phase 3Active not recruitingVectivBio AG1582021-07-132025-07-02
Evaluation of Long Term Safety and Efficacy of Glepaglutide in Treatment of SBS - Extension Trial
Glepaglutide - Short Bowel Syndrome
Phase 3CompletedZealand Pharma842021-06-162026-09-08
Trial to Evaluate Efficacy and Safety of Apraglutide in SBS-IF
apraglutide - Short Bowel Syndrome
Phase 3CompletedVectivBio AG1642021-01-262024-11-27
Evaluation of Long Term Safety and Efficacy of Glepaglutide in Treatment of SBS
glepaglutide - Short Bowel Syndrome
Phase 3CompletedZealand Pharma1502019-05-072026-09-08
Efficacy And Safety Evaluation of Glepaglutide in Treatment of Short Bowel Syndrome (SBS)
glepaglutide, Placebo - Short Bowel Syndrome
Phase 3CompletedZealand Pharma1062018-10-042025-07-17
Safety, Efficacy and Pharmacokinetic Study of Teduglutide in Infants 4 to 12 Months of Age With Short Bowel Syndrome
Teduglutide, Standard Medical Therapy, Syringe - Short Bowel Syndrome
Phase 3CompletedShire102018-08-312021-05-11
An Extension Study of Teduglutide in Japanese Participants With Short Bowel Syndrome Who Completed 24 Weeks of Treatment in SHP633-306 or TED-C14-004
Teduglutide, Syringe, Needle - Short Bowel Syndrome
Phase 3CompletedTakeda112018-07-092023-03-15
Study of Teduglutide in Japanese Participants With Short Bowel Syndrome
Teduglutide, Syringe, Needle - Short Bowel Syndrome
Phase 3CompletedShire72018-07-062020-08-04
A Study in Japanese Children With Short Bowel Syndrome Who Completed SHP633-302
Teduglutide - Short Bowel Syndrome
Phase 3CompletedShire92017-08-232022-05-24
Safety and Efficacy Study in Infant With SBS
NTRA-9620, Placebo - Short Bowel Syndrome
Phase 2 / Phase 3TerminatedElgan Pharma Ltd.22017-03-202021-10-12
Study in Japanese Pediatric Subjects With Short Bowel Syndrome (SBS) Who Are Dependent on Parenteral Support
Teduglutide - Short Bowel Syndrome
Phase 3CompletedShire102017-01-132022-02-02
Long-term Safety and Efficacy Study of Teduglutide in Pediatric Participants With Short Bowel Syndrome (SBS)
TED, SOC, Syringe - Short Bowel Syndrome
Phase 3CompletedShire612017-01-092025-03-28
Long-term Study of Teduglutide in Pediatric Subjects With Short Bowel Syndrome Who Completed the TED-C13-003 Study
Teduglutide, SOC - Short Bowel Syndrome
Phase 3CompletedShire292016-12-092025-03-19

Showing 20 of 35. Sign in to see all of them.

Narrower conditions

Hyperphagia (6)  ·  Intestinal Failure (4)  ·  Cholestasis (3)  ·  Gastrointestinal Diseases (3)  ·  Digestive System Diseases (2)  ·  Intestinal Diseases (2)  ·  Malabsorption Syndromes (2)  ·  Pathologic Processes (2)  ·  Postoperative Complications (2)  ·  Colitis, Ulcerative (1)  ·  Gastroschisis (1)  ·  Infant, Premature, Diseases (1)  ·  Intestinal Atresia (1)  ·  Pathological Conditions, Signs and Symptoms (1)

Broader conditions

Pathological Conditions, Signs and Symptoms (34)  ·  Digestive System Diseases (33)  ·  Intestinal Diseases (33)  ·  Malabsorption Syndromes (33)  ·  Pathologic Processes (33)  ·  Postoperative Complications (33)  ·  Gastrointestinal Diseases (32)  ·  Signs and Symptoms (6)  ·  Signs and Symptoms, Digestive (6)  ·  Bile Duct Diseases (3)  ·  Biliary Tract Diseases (3)  ·  Metabolic Diseases (2)  ·  Nutritional and Metabolic Diseases (2)  ·  Colitis (1)  ·  Colonic Diseases (1)

Interventions

teduglutide (16)  ·  ALX-0600 (6)  ·  Needles (4)  ·  Syringes (4)  ·  apraglutide (3)  ·  fish oil triglycerides (3)  ·  Glucagon-Like Peptide 2 (1)  ·  Loperamide (1)  ·  Standard of Care (1)

Sponsors

Shire (14)  ·  Zealand Pharma (6)  ·  Takeda (3)  ·  VectivBio AG (3)  ·  Marathon Pharmaceuticals, LLC (2)  ·  Chongqing Peg-Bio Biopharm Co., Ltd. (1)  ·  Elgan Pharma Ltd. (1)  ·  Hospices Civils de Lyon (1)  ·  Kapiolani Medical Center For Women & Children (1)  ·  Mark Puder (1)  ·  Odense University Hospital (1)  ·  University of Oklahoma (1)

Countries

United States (23)  ·  United Kingdom (16)  ·  France (14)  ·  Denmark (13)  ·  Belgium (12)  ·  Germany (12)  ·  Poland (12)  ·  Canada (10)  ·  Italy (9)  ·  Japan (9)  ·  Netherlands (8)  ·  Spain (6)  ·  Finland (4)  ·  Hungary (4)  ·  Argentina (3)

Top investigators

Tomasz Masior (2)  ·  Huanlong Qin (1)  ·  Kimberly D Ernst, MD, MSMI (1)  ·  Lynn M Iwamoto, MD (1)  ·  Niels Qvist, MD, DMsc (1)

Results publications

PMID 37364133, PMID 21317170, PMID 24134154, PMID 27507402, PMID 37889619, PMID 38873891, PMID 41858082, PMID 16099790, PMID 19661785, PMID 21975668, PMID 22982184, PMID 23274148, PMID 23333663, PMID 23587733, PMID 27855998, PMID 28627732, PMID 29174926, PMID 29761915, PMID 31784300, PMID 32059815, PMID 32341691, PMID 33038344, PMID 34695449, PMID 39708985, PMID 41454663

NIH funding

2004 (2), 2016 (2), 2008 (1), 2009 (1), 2017 (1), 2025 (1)